BACKGROUND A significant share of the cost of cancer care is concentrated in the end‐of‐life
period. Although quality measures of aggressive treatment may guide optimal care during …

Background:Longitudinal, patient-level data on resource use and costs after an ischemic
stroke are lacking in Canada. The objectives of this analysis were to calculate costs for the first …

Background: With recent advances in the treatment of non-small-cell lung cancer (NSCLC)
and current fiscal constraints within publicly funded health care systems, understanding the …

Importance Melanoma treatment has evolved during the past decade with the adoption of
adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on …

BACKGROUND. The study aimed to compare the cost‐effectiveness of concomitant and
adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme …

Purpose To evaluate whether the early identification of patients who may benefit from palliative
care impacts on the use of palliative, community and acute-based care services. Methods …

Background: Previous costing and resource estimates for cancer have not been complete
owing to lack of comprehensive data on cancer-related medication and radiation treatment. …

Background To improve the precision of health economics analyses in oncology, reference
datasets of health utility (HU) scores are needed from cancer survivors across different …

Purpose The 21-gene assay Oncotype Dx (Genomic Health, Redwood City, CA) test is used
to aid the decision about chemotherapy in patients with hormone receptor–positive breast …

Background There is a lack of evidence on the economic burden of managing cervical cancer
in the public payer Canadian setting. Objective We used individual patient-level data to …